Supervisory authorities



Home > Directory > CHEMBIO

CNRS Researcher



  • Sept 2011- jan 2015 : Shared PhD degree between the University of Burgundy (Dijon, France) and the University of Groningen (Groningen, The Netherlands) on the synthesis and anticancer evaluation of gold-based complexes.
  • 2009-2011: Master Molecular Chemistry and Green Processes, University of Burgundy (Dijon, France).
  • 2008/2009: Bachelor in Sciences, technology and health option chemistry, University of Burgundy (Dijon, FRANCE).


  • Oct. 2018-: CNRS Researcher at Sorbonne Université, Institut Parisien de Chimie Moléculaire, Chembio team on the synthesis and study of gold complexes associated to biomelecules for therapy and biocatalysis.
  • Oct. 2017-Sept. 2018 : Post-doctoral research associate in Prof. Thorimbert group on the synthesis of theranostic compounds based on heteropolycyclic ligands. (Institut Parisien de Chimie Moléculaire, UPMC, Paris, France).
  • Feb. 2015-Sept. 2017: Post-doctoral research associate in Prof. Bochmann group on the synthesis of cyclometallated gold(III) for photoluminescence and anticancer applications (Scool of Chemistry, University of East Anglia, Norwich, Royaume-Uni).
  • 2013: Research stay in Pr. Maria Agostina Cinellu in the University of Sassari (Sassari, Italy) on the synthesis of cyclometalated Au(III) complexes for anticancer applications.
  • 2013: Laureate of the Autumn Eole grant from the French-Dutch Network for exchange between France and The Netherlands.
  • 2011: 6-months internship in design and synthesis of organometallic anticancer treatments in Pr. Pierre LE GENDRE’s group, University of Burgundy (Dijon, France).
  • 2010-2011: Laureate of the Master 2 grant from the Regional Council of Burgundy.
  • 2010: 4-months internship in biological characterization of anti-cancer metallodrugs in Pr. Paul J. DYSON’s group, Ecole Polytechnique Fédérale de Lausanne (Lausanne, Switzerland).


Solid knowledge in:

  • Organical and macromolecular synthesis and electrosynthesis.
  • Coordination chemistry and structural analysis.
  • Modelisation and reactionnal mechanisms.
  • Catalysis and non-usual medium.
  • Precursors of original materials.
  • Cell culture, viability measurement in vitro and ex vivo
  • Biological analysis.

H index: 12


  • Cyclometallated Au(III) dithiocarbamate complexes: synthesis, anticancer evaluation and mechanistic studies, M. R. M. Williams, B. Bertrand,* D. L. Hughes, Z. A. E. Waller, C. Schmidt, I. Ott, M. O’Connell, M. Searcey,* M. Bochmann,* Metallomics, 2018, DOI: 10.1039/C8MT00225H
  • Acridine-decorated cyclometallated gold(III) complexes: synthesis and anti-tumour investigations, M. R. M. Williams, B. Bertrand,* J. Fernandez-Cestau, Z. A. E. Waller, M. A. O’Connell, M. Searcey,* M. Bochmann,* Dalton Trans. 2018, DOI: 10.1039/C8DT02507J
  • Gold(III) complexes for anti-tumour applications: an overview, B. Bertrand,* M. R. M. Williams, M. Bochmann,* Chem. Eur. J. 2018, 24, 11840-11851. Showcase review
  • A gold(III) pincer ligand scaffold for the synthesis of binuclear and bioconjugated complexes: synthesis and anticancer potential, B. Bertrand,* M. A. O’Connell, Z. A. E. Waller, M. Bochmann, Chem. Eur. J. 2018, 24, 3613-3622.
  • Synthesis, structure and cytotoxicity of cyclic (alkyl)(amino) carbene and acyclic carbene complexes of group 11 metals, B. Bertrand,* A. S. Romanov, M. Brooks, J. Davis, C. Schmidt, I. Ott, M. A. O’Connell,* M. Bochmann,* Dalton Trans., 2017, 46, 15875-15887.
  • (C^Npz^C)AuIII complexes of acyclic carbene ligands: synthesis and anticancer properties
    M. Williams, A. I. Green, J. Fernandez-Cestau, D. L. Hughes, M. A. O’Connell, M. Searcey, B. Bertrand,* M. Bochmann, Dalton Trans. 2017, 46, 13397-13408.
  • Synthesis, structures, and properties of luminescent (C∧N∧C)gold(III) alkyl complexes: correlation between photoemission energies and C–H acidity. J. Fernandez-Cestau, B. Bertrand, A. Pintus, M. Borchmann, Organometallics, 2017, 36, 3304-3312.
  • Cytotoxicity of pyrazine-based cyclometalated (C^Npz^C)Au(III) carbene complexes: Impact of the nature of the ancillary ligand on the biological properties. B. Bertrand,* J. Fernandez-Cestau, J. Angulo, M. M. D. Cominetti, Z. A. E. Waller, M. Searcey, M. A. O’Connell, M. Bochmann, Inorg. Chem. 2017, 56, 5728-5740.


Main oral presentations

  • Juillet 2018 : GOLD 2018, Paris, France, Titre : Pyrazine-based cyclometalated (C^Npz^C)Au(III) complexes: from simple NHC complexes to bioconjugates
  • Juin 2017 : 14ème ISABC, Toulouse, France. Titre : Bioconjugated pyrazine-based cyclometalated (C^Npz^C)Au(III) complexes: synthesis and anticancer potential.
  • Septembre 2016 : 2nd Southern Dalton meeting, Reading, Royaume-Uni. Titre : Pyrazine-based cyclometalated (C^Npz^C)Au(III) complexes: impact of the nature of the ancillary ligand on the biological properties Prix de présentation orale.
  • Août 2014 : 2nd WHAM meeting, Zurich, Suisse. Titre : Caffeine-based gold(I)-N-heterocyclic carbine complexes: synthesis and anticancer evaluation.